734-936-8000 - Service Desk | Request Support

General Medicine Journal Club: JAMA/NEJM/Annals of Internal Medicine, presented by Kassandra Weber

To begin this activity, click Enroll. Once logged in, learners can access educational content, assessments, and evaluations. Learners who successfully complete the activity will be able to print a certificate.

Step Status
Educational Materials
Release Date: Fri, 4/15/22
Termination Date: Mon, 3/31/25
Credits: 1

General Medicine Journal Club: JAMA/NEJM/Annals of Internal Medicine

Presenter: Kassandra Weber, MD

This lecture was originally presented during RSSNAME held on 02/08/2022.
There are no relevant financial relationships to disclose for this activity.
Target Audience: This activity is appropriate for Nurse Practitioners, Physician Assistants, Physicians in the fields of Family Medicine, Internal Medicine.
Accreditation and Credit Designation:

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Original Release Date: April 2022
Termination Date: April 2025

Additional Info: Bibliographic Resources

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Bodyweight in Adults With Overweight or Obesity Without Diabetes
The STEP 8 Randomized Clinical Trial
Rubino DM, Greenway FL, Khalid U, et al.
JAMA. 2022 Jan 11;327(2):138–150.

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Gottlieb RL, Vaca CE, Paredes R, et al. PINETREE Investigators
N Engl J Med. 2022 Jan 27;386(4):305-315.

Risk for Recurrent Venous Thromboembolism in Patients with Subsegmental Pulmonary Embolism Managed Without Anticoagulation
Le Gal G, Kovacs MJ, Bertoletti L, et al.
Ann Intern Med. 2022 Jan;175(1):29-35.

Risk for Recurrent Venous Thromboembolism and Bleeding with Apixaban Compared with Rivaroxaban: An Analysis of Real-World Data. Dawwas GK, Leonard CE, Lewis JD, Cuker A. Ann Intern Med. 2022 Jan;175(1):20-28.

Credits available:

AMA PRA Category 1: 1.00
Participation: 1.00